The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2022 | Optimizing CAR-T therapy in LBCL
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, explores potential avenues for improving chimeric antigen receptor T-cell (CAR-T) therapy in large B-cell lymphoma (LBCL), including optimizing the design of CAR-Ts to enhance efficacy or reduce toxicity, improve the patient selection and referral processes, and investigating the efficacy of CAR-T combinations with other agents used to treat lymphoma. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Transcript
Well, that was at the peak of my presentation during one of the Satellite Symposia on Sunday, and there are actually many avenues for improvements. Some potential improvements are related to the design of the chimeric antigen receptor itself with a view to improve efficacy to induce long-lasting remissions in a higher fraction of patients, or with a view to mitigate the side effects and potentially simplify the hospital organization needed to care for these side effects...
Well, that was at the peak of my presentation during one of the Satellite Symposia on Sunday, and there are actually many avenues for improvements. Some potential improvements are related to the design of the chimeric antigen receptor itself with a view to improve efficacy to induce long-lasting remissions in a higher fraction of patients, or with a view to mitigate the side effects and potentially simplify the hospital organization needed to care for these side effects.
Other avenues relate to the patient selection process, the referral process to the treating hospitals, and others relate to potential combinations of CAR-Ts with other agents that are being used to treat lymphoma. One has to think of CAR-Ts as being an important step in an otherwise quite complex therapeutic path, so again, selection and proper referral of the patients at the most appropriate time will be key to improved access to these treatments.
Obviously, it is of utmost importance that we improve the fraction, the proportion of patients, who do benefit from receiving CAR-Ts, and investigating the tumor biology, as well as the T-cell fitness characteristics, will help us to better delineate which patients can benefit off these innovative therapies and which could benefit off other choices.
Read more...
Disclosures
Honorarium from Bellicum Pharmaceuticals / BMS Celgene / Kite Gilead / Novartis / Janssen Pharmaceuticals
